

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 7, 2017

Juno Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36781
(Commission
File Number)

46-3656275
(IRS Employer
Identification No.)

**400 Dexter Avenue North, Suite 1200
Seattle, Washington 98109**
(Address of principal executive offices, including zip code)

(206) 582-1600
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On November 7, 2017, the Board of Directors (the "Board") of Juno Therapeutics, Inc. ("Juno"), upon recommendation of the Compensation Committee of the Board, increased the base salaries of each of Hans E. Bishop, Bernard J. Cassidy, and Steven D. Harr, effective November 12, 2017, as follows:

Named Executive Officer	Previous Base Salary	New Base Salary
Hans E. Bishop	\$500,000	\$640,000
Bernard J. Cassidy	\$390,000	\$400,000
Steven D. Harr	\$424,360	\$540,000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Juno Therapeutics, Inc.

By: /s/ Bernard J. Cassidy
Bernard J. Cassidy
General Counsel & Corporate Secretary

Date: November 9, 2017